Drug therapy of cardiac arrhythmias.
The authors provide an overview of the general features of pharmacokinetics and report the pharmacodynamic and pharmacokinetic interactions of selected antiarrhythmic drugs. Their clinical experience in the use of investigational antiarrhythmic drugs is also presented.
D000638:Amiodarone / Q000627:therapeutic use; D000813:Anilides / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000097:blood / Q000627:therapeutic use*; D001073:Aprindine / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D001682:Biological Availability; D016700:Encainide; D006207:Half-Life; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D007408:Intestinal Absorption; D007700:Kinetics; D008012:Lidocaine / Q000031:analogs & derivatives / Q000627:therapeutic use; D008657:Metabolic Clearance Rate; D008801:Mexiletine / Q000627:therapeutic use; D011405:Propafenone; D011427:Propiophenones / Q000627:therapeutic use; D011485:Protein Binding; D013610:Tachycardia / Q000188:drug therapy; D016677:Tocainide
D000813:Anilides; D000889:Anti-Arrhythmia Agents; D007093:Imidazoles; D011427:Propiophenones; D008801:Mexiletine; D016677:Tocainide; D001073:Aprindine; D011405:Propafenone; D008012:Lidocaine; D000638:Amiodarone; D016700:Encainide; C032151:cifenline